Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy

Sammy Saab
Department of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Background: Overt hepatic encephalopathy (HE), which is associated with neuropsychiatric symptoms and neuromuscular dysfunction in patients with liver cirrhosis, is often managed in the hospital setting. Approximately 60% of eligible patients do not receive prophylactic therapy after an overt HE episode.

Objective: The aim of this review is to evaluate the impact of rehospitalization on costs and clinical outcomes in HE.

Methods: A PubMed search of English-language articles through July 9, 2014 was conducted, and bibliographies of identified publications were reviewed. Abstracts from relevant professional society meetings from 2010 to 2014 were searched. The selected references and abstracts reported on the prevalence, costs, or clinical consequences of rehospitalization in adults with HE.

Data synthesis: HE is a key reason for readmission among patients hospitalized for complications of cirrhosis. Almost 40% of patients previously hospitalized for HE may be readmitted within 1 year for HE-related reasons. Furthermore, in-hospital US mortality for patients admitted for HE is about 7% to 15%. Recurrent HE and hospitalization for cirrhosis complications are associated with impaired quality of life. In addition, recurrences (especially those requiring hospitalization) may contribute to persistent cognitive deficits (eg, impairments in reaction time, attention, and working memory) after resolution of an acute episode of overt HE.

Conclusion: The economic and clinical consequences of rehospitalization for patients with overt HE underscore the importance of secondary prevention and highlight the need to identify reasons for the undertreatment of patients after hospitalization for overt HE.

Keywords: hospitalization, lactulose, prevention, rifaximin, cirrhosis, cognitive impairment

Introduction
Hepatic encephalopathy (HE) is a potentially reversible condition associated with neuropsychiatric symptoms and neuromuscular dysfunction of varying severity. HE is caused by liver insufficiency, portosystemic shunting, or both. HE comprises a spectrum of abnormalities spanning a range from minimal (covert) HE (eg, subtle alterations in cognitive function determined via neuropsychometric tests) to overt HE (eg, evaluable clinical symptoms, such as generalized motor dysfunction with alterations in consciousness). Additionally, as the condition progresses from minimal HE to overt HE, patients and caregivers may report personality changes, such as apathy, lack of inhibition, and irritability. Sleep disturbances (eg, reversal of the sleep–wake cycle) and changes in motor function (eg, development of asterixis) and consciousness may also be observed.

HE is a common complication of decompensated cirrhosis. Up to 40% of patients with cirrhosis eventually develop overt HE, and many patients experience repeated
episodes (ie, recurrence).\(^2,^4\) The presence of overt HE at the time of an initial diagnosis of cirrhosis has been reported in 10% to 14% of patients overall, in 16% to 21% of patients diagnosed with decompensated cirrhosis, and in 10% to 50% of patients with a transjugular intrahepatic portosystemic shunt.\(^2\) The prognosis after developing overt HE is poor, with a 1-year survival rate as high as 40% to 50% and a 3-year survival rate of approximately 20% .\(^3,^4\) In a study of US adults on the United Network for Organ Sharing and Organ Procurement and Transplantation Network registry waitlist for liver transplantation, patients with severe (grade 3–4) overt HE at the time of waitlist registration had a significantly greater risk of 90-day mortality than patients without HE (hazard ratio, 1.6; 95% confidence interval, 1.4, 1.9; \(P<0.001\)).\(^7\)

HE can progress quickly, and the severity of symptoms often leads to patients being hospitalized for treatment.\(^1\) In the 2006 Nationwide Inpatient Sample, which included 65,072 discharge records involving hospitalizations due to complications of cirrhosis, 41% of cirrhosis-related hospitalizations requiring critical care were associated with HE.\(^5\) The number of hospital discharges associated with HE based on codes from the *International Classification of Diseases, Ninth Revision, Clinical Modification* has progressively increased since 2004 and exceeded 400,000 in 2010.\(^6,^9\) Based on the Nationwide Inpatient Sample, the estimated hospitalization incidence for patients with HE as a primary or secondary diagnosis ranged from 102,293 in 2005 to 115,814 in 2009; the prevalence was 0.33% of all hospitalizations.\(^11\) Although hospitalizations related to HE have been increasing, for patients with a primary diagnosis of HE, the mean length of stay decreased between 1993 and 1996 in the USA and has subsequently remained constant at approximately 6 days.\(^3,^{12-14}\) On average, the length of stay included 0.9 days in the intensive care unit, based on an analysis of a large US hospital database (June 2010 to December 2011).\(^14\)

Although the burden and cost of initial hospitalization for HE and other factors such as treatment for HE generally have been characterized, it is not apparent that the risks and costs associated with rehospitalization have been studied to the same extent. Indeed, the risk of rehospitalization for patients with cirrhosis appears to be substantial. In a retrospective study of patients with decompensated cirrhosis, 69% (276) of 402 records showed >1 readmission related to complications, with a median time to first readmission of 67 days.\(^15\) The authors reported a median number of readmissions of two (range, 0–40); however, readmissions could have resulted from any of the reported complications of cirrhosis and were not limited to HE.

The objective of this systematic review is to evaluate the impact of rehospitalization on costs and clinical outcomes for patients with cirrhosis initially hospitalized for HE.

**Methods**

A systematic review of the PubMed medical literature was conducted for English-language articles with no time limitation (up to February 18, 2015). The primary search was performed using the keywords “hepatic encephalopathy”, “hospitalization”, “admission”, “rehospitalization”, and “readmission”. To ensure all relevant articles were identified, additional (secondary) search terms and search strings were tested with the following keywords: “quality of life”, “factor”, “predictors”, “mortality”, “survival”, “transplantation”, “burden”, “cost”, “no treatment”, “untreated”, “placebo”, and “prophylaxis”. Selection criteria (papers discussing randomized, controlled trials; observational studies; and meta-analyses) were applied to the initial searches to enrich the quality of the studies reported. These criteria were later relaxed to expand the pool of eligible studies to include open-label, retrospective, uncontrolled, and cross-sectional study designs. Bibliographies of identified publications were also reviewed for relevant references that had escaped detection using the predefined search terms.

Because the initial literature search identified a relatively low number of studies, the review was expanded to include abstracts published for pertinent medical conferences between 2010 and 2014. Included were abstracts for the American College of Gastroenterology annual meeting, Digestive Disease Week, The Liver Meeting\(^8\) (American Association for the Study of Liver Diseases), and The International Liver Congress\(^TM\) (European Association of the Study of the Liver), based on a search for “encephalopathy”. The search of medical conferences was limited to those taking place in the last 5 years at the time the initial searches were conducted; the author anticipated a larger number of studies would be identified in the PubMed literature. All references and abstracts selected for inclusion reported on the prevalence, costs, or clinical consequences of rehospitalization in adult patients with HE.

**Results**

Outcomes of the systematic search are summarized in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram (Figure 1). Results of the PubMed search yielded 95 studies; an additional 27 studies were identified from medical conferences (n=9) and secondary search terms (n=18). Studies from the
latter category included pertinent data for inclusion in the review that were not identified when the primary search string was performed. Of those studies initially identified, the majority (n=92) were excluded upon further review. The primary reasons for exclusion were studies in animals, hospitalization attributed to other complications of cirrhosis, acute liver disease, and initial hospitalization event without recurrence, among others. This review includes results from 12 journal publications and six abstracts (Table 1). 6,8,9,11,12,14,16–27

Readmission rates in patients with HE
A retrospective analysis of data from >500 US hospitals assessed hospital readmissions in 8,766 adults discharged from the hospital between June 2010 and December 2011 with a primary diagnosis of HE. 14 Overall, 17.6% of discharged patients were readmitted within 30 days, and 39.5% were readmitted within 1 year for HE-related reasons. Incidence rates for all-cause readmission were 27.4% at 30 days and 56.4% at 1 year. In another retrospective US study, approximately one-third of 402 patients with decompensated cirrhosis had HE at admission, 78% (314 of 402) of patients were readmitted during a median follow-up period of 203 days, with 88% (276 of 314) of patients having ≥1 non-elective readmission. 22 The median time to first readmission was 67 days, with 14% of patients readmitted within 1 week and 37% within 1 month. Overall, 22% of readmissions within 1 month were considered preventable. In fact, recurrent HE was among the most preventable reasons for readmission. Notably, after adjusting for potential confounding factors, patients with more frequent readmissions had a significantly increased risk of mortality.

Furthermore, a retrospective review analyzed data from 139 patients admitted to a US tertiary hospital for the treatment of complications of liver cirrhosis and reported that HE was an indication for admission in 36% of these patients. 24,25 Of the 31% of patients readmitted within 1 month, 47% were readmitted for HE. In an attempt to analyze possible causes of readmission due to HE, an analysis of medical records of 145 patients admitted with overt HE to a single hospital identified poor social support, failure to fill a prescription, and lack of follow-up with a health care provider as factors associated with a high likelihood of readmission. 26

Costs of hospitalization
Hospitalization for HE is associated with substantial economic burden. The total national cost of hospitalizations of patients with HE (primary or secondary diagnosis) increased from US$1.7 billion in 2005 to US$2.0 billion in 2009. 11 The total cost per HE-related hospital discharge increased from US$22,511 in 2004 to US$37,598 in 2010. 9 This analysis included patients with any International Classification of Diseases, Ninth Revision, Clinical Modification discharge diagnosis code indicative of HE (ie, not limited to patients with a primary or secondary diagnosis of HE). The mean hospital cost for HE-related hospitalization (primary or secondary diagnosis) did increase between 2005 (US$16,512) and 2009 (US$17,812), but the difference was not statistically significant. 11 A study reported that the mean hospital cost in 2003 for patients admitted with a primary diagnosis of
Table 1 Relevant published studies of the impact of rehospitalization costs and clinical outcomes in hepatic encephalopathy (HE)

<table>
<thead>
<tr>
<th>Study design</th>
<th>Setting</th>
<th>Population</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-sectional study</td>
<td>US university medical center</td>
<td>160 consecutive adults with cirrhosis presenting for initial liver transplantation</td>
<td>Patients with cirrhosis had lower SF-36&lt;sup&gt;6&lt;/sup&gt; scores than the general US population. Advanced cirrhosis was associated with significantly lower PCS scores and RP (&lt;0.01), BP (&lt;0.037), GH (&lt;0.028), and SF (&lt;0.034) domains. Patients with minimal HE performed significantly worse on cognitive testing than normal cirrhotic patients. Psychometric scores highly correlated with number of HE episodes and hospital admissions for overt HE. Probiotic use significantly reduced hospitalizations for breakthrough episodes of HE, with concomitant improvements in HRQOL. Probiotic use was associated with SF-36 improvement in physical function, role physical, and physical component summary domains.</td>
</tr>
<tr>
<td>Cross-sectional study</td>
<td>Outpatient clinics in two US university medical centers</td>
<td>Part A: 226 patients with (n=54) or without (n=172) history of overt HE Part B: 50 patients with cirrhosis who had experienced ≥ 1 overt HE episode</td>
<td>Overall mortality rate at 1 year of 54% (36/66), with a 39.5% in-hospital mortality rate. Cost of hospitalization for advanced encephalopathy of US$23,192. Lactulose monotherapy and rifaximin salvage were found to be potentially cost-effective.</td>
</tr>
<tr>
<td>Randomized, double-blind, placebo-controlled study</td>
<td>Tertiary-level health care center in Chandigarh, India</td>
<td>130 patients with cirrhosis who had recovered from a previous episode of HE in the prior month</td>
<td>HE adversely affects patient QOL and presents a burden on caregivers. HE awareness is poor in patients with cirrhosis and their caregivers, attributed to a deficit in information being distributed.</td>
</tr>
<tr>
<td>Retrospective chart review</td>
<td>Medical ICU in French university hospital</td>
<td>71 patients with severe HE</td>
<td>Cost per HE discharge increased by &gt;50% between 2004 and 2010. Cause of the cost increase may be attributed to new therapies that are more beneficial. In-hospital mortality rate of 48% (10/21 patients). Those at risk for HE should be routinely screened to detect latent encephalopathy.</td>
</tr>
<tr>
<td>Decision-analysis model</td>
<td>Analysis conducted from perspective of US third-party payer</td>
<td>NA</td>
<td>Cumulative hospital charges for a primary diagnosis of HE increased substantially from 1993 to 2003, totaling approximately US$7 billion. Future economic evaluations should identify therapies that positively impact clinical and economic outcomes. Total charges for HE-related hospitalizations increased from US$4.7 billion in 2005 to US$7.3 billion in 2009, a 55% increase. The inpatient mortality rate for patients with HE decreased from 15.6% in 2005 to 14.4% in 2009 (P=NS). Inpatient hospitalizations for advanced liver disease and HE complications are increasing, with consistent increases in socioeconomic and financial burden. The in-hospital mortality rate is high for patients with HE: 33% for chronic cases and 64% for acute cases. High bilirubin levels were prognostic of poor outcomes in patients with chronic liver disease.</td>
</tr>
<tr>
<td>Cross-sectional study</td>
<td>Specialist clinic at an Italian university medical center</td>
<td>35 consecutive outpatients with cirrhosis and history of overt HE episodes and chronic treatment referred to specialist clinic for formal evaluation; 31 caregivers</td>
<td>Patients with any ICD-9-CM discharge diagnosis indicative of HE.</td>
</tr>
<tr>
<td>Prospective, observational study</td>
<td>Medical wards of the Lagos State University Teaching Hospital, Ijega</td>
<td>21 patients with HE and a background of liver disease</td>
<td>Patients with any ICD-9-CM discharge diagnosis of HE.</td>
</tr>
<tr>
<td>Nationwide Inpatient Sample data analysis</td>
<td>Nationwide Inpatient Sample (2002)</td>
<td>40,012 patients with primary diagnosis of HE</td>
<td>Patients with any ICD-9-CM discharge diagnosis of HE.</td>
</tr>
<tr>
<td>Nationwide Inpatient Sample data analysis</td>
<td>Nationwide Inpatient Sample (2005–2009)</td>
<td>33.3 million hospitalizations, including 111,090 hospitalizations with HE</td>
<td>Patients with any ICD-9-CM discharge diagnosis of HE.</td>
</tr>
<tr>
<td>Nationwide Inpatient Sample data analysis</td>
<td>Medical ICU at Indian university hospital</td>
<td>50 consecutive patients admitted with HE associated with acute or chronic liver disease</td>
<td>Patients with any ICD-9-CM discharge diagnosis of HE.</td>
</tr>
</tbody>
</table>
Volk et al. Retrospective chart review, US university health system medical center. 402 patients with decompensated cirrhosis; 276 patients with ≥1 non-elective readmission.

- There was a median rate of three hospitalizations per person-years for patients with decompensated cirrhosis.
- Patients who were more often readmitted to the hospital had higher risk of subsequent mortality (hazard ratio, 1.08; P=0.001).
- The mean cost of readmission within 4 weeks of discharge was US$20,581.

Meeting abstracts

Congly et al. Cost-utility analysis using Markov model based on clinical trial data. Patients with history of HE.

- The model predicts 5-year survival rates of 32%, 30%, and 24.5% for patients treated with rifaximin (upfront), rifaximin (salvage), and lactulose, respectively.
- The largest drivers of cost were hospitalization and rifaximin use.
- Adding rifaximin to treatment regimens may be cost-effective.
- 41% of hospitalizations among patients with cirrhosis were attributed to encephalopathy.
- Encephalopathy was associated with a two-fold higher probability of inpatient mortality (P<0.01).

Kim et al. Nationwide Inpatient Sample data analysis. 65,072 discharge records associated with hospitalization for complications of cirrhosis.

- 1-year retrospective chart review, US university tertiary hospital. 139 patients admitted with a complication related to liver cirrhosis (36% with HE).
- 31% of patients overall were readmitted within 30 days; 47% of these cases were attributed to HE.
- This model can be used to identify patients at higher risk for readmission, which may afford an opportunity for quality improvement.
- 36% of hospital admissions for liver cirrhosis were attributed to HE.
- HE was the most common cause of readmission within 30 days, followed by fluid overload.
- In-hospital mortality rate was 7.3%.
- Mean cost per hospitalization was US$10,629.
- Incidence rates for all-cause readmissions were 27.4% (30 days) and 56.4% (1 year); rates for HE-related readmissions were 17.6% (30 days) and 39.5% (1 year).
- Predictors of hospital readmission included lack of compliance, lack of provider follow-up, lack of social support, type of insurance (Medicaid, insurance, or no insurance), and lack of employment.
- New methods are needed to identify patients at risk for readmission and to deliver value-based medicine.

Masadeh et al. 1-year retrospective chart review, US university tertiary hospital. 139 patients admitted with a complication related to liver cirrhosis (36% with HE).

- 36% of hospital admissions for liver cirrhosis were attributed to HE.
- HE was the most common cause of readmission within 30 days, followed by fluid overload.
- In-hospital mortality rate was 7.3%.
- Mean cost per hospitalization was US$10,629.
- Incidence rates for all-cause readmissions were 27.4% (30 days) and 56.4% (1 year); rates for HE-related readmissions were 17.6% (30 days) and 39.5% (1 year).
- Predictors of hospital readmission included lack of compliance, lack of provider follow-up, lack of social support, type of insurance (Medicaid, insurance, or no insurance), and lack of employment.
- New methods are needed to identify patients at risk for readmission and to deliver value-based medicine.

Neff et al. Premier Research Database analysis. 8,766 patients discharged from June 2010 to December 2011 with primary diagnosis of HE.

- 145 patients with ≥1 hospitalization for overt HE within a 6-month period.

Abbreviations: BP, bodily pain; GH, general health perception; HCUP, Healthcare Cost and Utilization Project; HE, hepatic encephalopathy; HRQOL, health-related quality of life; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; ICU, intensive care unit; NA, not applicable; NS, not significant; PCS, physical component summary; QOL, quality of life; RP, role limitation-physical; SF, social functioning; SF-36, Short Form (36) Health Survey.
HE was US$23,192.12 The mean cost of hospitalization for HE (as a primary diagnosis) in a large (>500) US hospital database (June 2010 to December 2011) was US$10,629, with room and board accounting for approximately 50% of overall hospitalization costs (mean, US$5,518) and pharmacy costs accounting for 11.5% of overall hospitalization costs (mean, US$1,223).14

In a study of a university health system, the mean cost of readmission for patients with decompensated cirrhosis was US$25,898 for readmission within 1 week and US$20,581 for readmission between weeks 1 and 4.22

Overall, these data underscore the high costs of hospitalization for HE and the economic impact of rehospitalization.

Impact on health-related quality of life
Cirrhosis and overt HE are both associated with impairment in health-related quality of life (QOL). In patients with cirrhosis and varying degrees of neuropsychiatric impairment, the severity of HE was significantly associated with patient QOL scores as well as the degree of caregiver burden.19

Among 160 consecutive adults with cirrhosis presenting for an initial evaluation for liver transplantation in a university setting between January 2001 and September 2001, 125 patients (78%) had HE (36 with minimal HE and 89 with overt HE).16 Compared with the general US population, patients with cirrhosis had poorer health-related QOL based on Short Form (36) Health Survey (SF-36) domain and summary scores. Patients with cirrhosis and overt HE experienced significantly worse physical and mental health-related QOL than those without HE. In addition, the reduction in health-related QOL related to HE was independent of the Child-Pugh score. Of note, the physical component summary score of the SF-36 was lower in patients with cirrhosis who had previously been hospitalized than in patients who had never been hospitalized. This observation may be related to an increase in disease severity among patients requiring hospitalization and may also be related to hospitalizations for complications of cirrhotic decompensation, such as HE.

Impact on cognitive function and residual cognitive impairment
Unfortunately, cognitive deficits have been shown to persist after an episode of overt HE resolves. In a cross-sectional study of 226 patients with cirrhosis, patients with a history of overt HE (n=54) performed significantly worse than patients without a history of overt HE (n=172) on psychometric tests.13 A cross-sectional study assessed cognitive function in 50 patients with cirrhosis who had experienced ≥1 episode of overt HE. Of the 50 patients, 32 were being treated with lactulose monotherapy, eleven were being treated with rifaximin monotherapy, and seven were being treated with rifaximin and lactulose combination therapy. All patients had normal mental status at the time of testing. In that study, the severity of cognitive impairment increased both with the number of episodes of overt HE and with the number of hospitalizations related to overt HE. Furthermore, the number of previous episodes and the number of hospitalizations for overt HE correlated with psychometric scores, which were used to assess severity of residual cognitive impairment (Table 2).17

Discussion
To reduce the risk of HE recurrence, the American Association for the Study of Liver Diseases and European Association of the Study of the Liver recommend prophylactic treatment after an episode of overt HE resolves.2 However, routine prophylaxis is not recommended for preventing HE after a transjugular intrahepatic portosystemic shunt.2 Medications commonly administered to prevent the recurrence of overt HE are similar to those for treating overt HE episodes and include lactulose and rifaximin – in fact, rifaximin is indicated for reducing the risk of overt HE recurrence in adults (Figure 2).2 Per treatment guidelines, “[r]ifaximin added to lactulose is the best-documented agent to maintain remission in patients who have already experienced one or more bouts of OHE [overt hepatic encephalopathy] while on lactulose treatment after their initial episode of OHE”2. Prophylactic therapy to prevent HE recurrence is usually continued indefinitely, until liver transplantation or death, but
Table 2 Correlation between psychometric tests and the number of hospitalizations for or episodes of overt hepatic encephalopathy (HE) (N=50)

<table>
<thead>
<tr>
<th>Psychometric test*</th>
<th>Cognitive function(s) evaluated</th>
<th>Number of hospitalizations for overt HE</th>
<th>Number of episodes of overt HE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digit symbol test (raw score)</td>
<td>Psychomotor speed, attention, and visual memory</td>
<td>( r = -0.39 ) ( P = 0.02 )</td>
<td>( r = -0.46 ) ( P = 0.009 )</td>
</tr>
<tr>
<td>ICT lures (n)</td>
<td>Response inhibition, attention, and working memory</td>
<td>( r = 0.50 ) ( P = 0.002 )</td>
<td>( r = 0.59 ) ( P = 0.001 )</td>
</tr>
<tr>
<td>ICT targets (% correct)</td>
<td>Reaction time</td>
<td>( r = -0.43 ) ( P = 0.009 )</td>
<td>( r = -0.44 ) ( P = 0.015 )</td>
</tr>
<tr>
<td>Number connection-A (speed)</td>
<td>Psychomotor speed</td>
<td>( r = 0.26 ) ( P = 0.144 )</td>
<td>( r = 0.22 ) ( P = 0.238 )</td>
</tr>
<tr>
<td>Number connection-B (speed)</td>
<td>Psychomotor speed, set shifting (ie, mental flexibility in switching between tasks), and divided attention</td>
<td>( r = 0.35 ) ( P = 0.047 )</td>
<td>( r = 0.35 ) ( P = 0.05 )</td>
</tr>
<tr>
<td>Block design test (raw score)</td>
<td>Visuomotor coordination, visuospatial reasoning, praxis, and psychomotor speed</td>
<td>( r = -0.11 ) ( P = 0.631 )</td>
<td>( r = -0.20 ) ( P = 0.378 )</td>
</tr>
</tbody>
</table>

Notes: Bold values indicate statistical significance. A high score on number connection-A, connection-B, and ICT lures, and a low score on digit symbol, block design, and ICT target number indicate poor psychometric performance. Adapted with permission from Gastroenterology, vol 138, no 7, Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy, pages 2332–2340, Copyright 2010 with permission from Elsevier.17

Abbreviation: ICT, inhibitory control test.

discontinuation may be considered if the precipitating factors have been well controlled or if a patient’s liver function or nutritional status has improved.2

Despite professional society recommendations for prophylactic therapy, many patients do not appear to be receiving preventive treatment after ≥1 episode of overt HE. An analysis of national claims for medical and hospital activity from 2009 to 2011 indicated that more than 60% of eligible patients with overt HE did not receive ongoing prophylactic therapy during each year studied.29 The apparent undertreatment of patients after an episode of overt HE may potentially result in preventable HE recurrences and, consequently, preventable rehospitalizations related to these recurrences. The burden and cost implications of undertreatment and potential resultant rehospitalizations for HE episodes were the subject of this review.

Hospital readmissions after discharge for decompensated cirrhosis, and for HE in particular, are common in patients with cirrhosis. In addition, a considerable number of patients are readmitted within 1 month of hospital discharge,14 and rehospitalization for HE imposes a substantial economic burden. Not surprisingly, statistical modeling data suggest that costs associated with hospitalization are some of the largest contributors to overall costs of HE treatment.23 Overall, given the various methodologies applied across studies to determine costs (eg, review of Current Procedural Terminology codes selected), it is difficult to compare results. Indeed, differences exist in the availability and interpretation of

![Figure 2](https://www.dovepress.com/)

**Figure 2** Acute and long-term management of overt hepatic encephalopathy (HE).  
**Notes:** Routine prophylaxis (lactulose or rifaximin) is not recommended for prevention of overt HE in patients with a transjugular intrahepatic portosystemic shunt. Data from Vilstrup H, Amodio P, Bajaj J. et al.1
Current Procedural Terminology codes, studies are conducted across divergent time periods in which health care inflation may vary considerably, studies prospectively enroll or retrospectively review cases of different patient populations with varied severity of disease, and services offered tend to become more complex and costly over time. In the present review, the data support a substantial cost burden associated with hospitalizations related to HE and suggest that the cost burden has increased over time.

Rehospitalization for HE may lead to adverse consequences for patients with cirrhosis, including increased mortality, impaired health-related QOL, and residual cognitive impairment. Regarding the effects of cognitive impairment, key findings from studies identified for this review support a hypothesis that repeated overt HE episodes may be neurotoxic and may lead to chronic neurologic damage, despite the apparent return of normal mental status initially after treatment. In a study by Bajaj et al.,

10 cognitive impairment was observed across all tests employed, including persistent and cumulative deficits in memory, response inhibition, and learning in patients who had experienced episodes of overt HE. The potential for persistent neurologic damage is an interesting hypothesis that has primarily been reported on in the context of patients observed after liver transplantation.

31 In one such study, cognitive dysfunction was more pronounced in patients who had experienced overt HE prior to liver transplantation.

31 Therefore, it will be important in the future to examine the potential for clinical and economic sequelae to extend beyond the primary HE episode.

Additionally, mortality rates remain high for patients with cirrhosis; however, some deaths attributed to an HE episode may be preventable. Notably, guidelines support the importance of prophylactic therapy to help prevent repeated episodes of overt HE in, and the consequent rehospitalization of, patients with cirrhosis.

Limitations

This review has several important limitations. For instance, most of the studies identified were not prospective but, rather, retrospective chart reviews, smaller cross-sectional studies, or sample surveys. In addition, there was significant heterogeneity in the outcomes measured in the identified studies. Nevertheless, data are accumulating to support the idea that HE-related rehospitalization represents an important unmet medical need. Because the published literature on HE-related rehospitalization is limited, this review included medical conference abstracts, which are considered by some to be less desirable sources of information. In addition, estimated hospitalization costs for HE were used as a proxy for rehospitalization costs in the absence of more specific data. Furthermore, for QOL and cognitive functioning, associations with rehospitalization were reported, but impairments may be related to HE recurrence rather than to rehospitalization per se.

Conclusion

The economic and clinical consequences of rehospitalization for patients with overt HE underscore the importance of secondary prevention. Nonetheless, about 60% of patients do not receive ongoing prophylactic therapy to prevent HE recurrence after discharge.24 It is unclear whether the low rate of prophylaxis is the result of patients not filling prescriptions or providers not prescribing prophylactic therapy. Further studies are warranted to help identify the reasons for the undertreatment of patients after hospitalization for overt HE to enable health care providers to better address this gap in medical care.

Acknowledgments

Technical editorial and medical writing assistance was provided, under the direction of the author, by Larry Nelson, PhD, and Mary Beth Moncrief, PhD, Synchrony Medical Communications, LLC, West Chester, PA, USA. Funding for this support was provided by Salix Pharmaceuticals, Inc., Raleigh, NC, USA.

Disclosure

Dr Saab serves as a consultant and on the speakers’ bureau for and holds stock in Salix Pharmaceuticals, Inc. The author declares no other conflicts of interest in this work.

References


